Small MAF genes variants and chronic myeloid leukemia

European Journal of Haematology

Volumn 92, Issue 1, 2014, Pages 35-41

  Martínez Hernández, Angelica ^a   Gutierrez Malacatt, Humberto ^b   Carrillo Sánchez, Karol ^a   Saldaña Alvarez, Yolanda ^a   Rojas Ochoa, Alberto ^c   Crespo Solis, Erick ^d   Aguayo González, Alvaro ^d   Rosas López, Adriana ^d   Ayala Sanchez, Jose Manuel ^e   Aquino Ortega, Xochitl ^e   Orozco, Lorena ^a,f   Cordova, Emilio J ^a  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f UNIVERSIDAD AUTÓNOMA DE LA CIUDAD DE MÉXICO   (Mexico)

Author keywords

MAFG; MAFK; Oxidative stress; Polymorphisms; Re sequencing

Indexed keywords

TRANSCRIPTION FACTOR MAF;

ARTICLE; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

MAFG; MAFK; OXIDATIVE STRESS; POLYMORPHISMS; RE-SEQUENCING;

ADULT; ALLELES; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAFF TRANSCRIPTION FACTOR; MAFK TRANSCRIPTION FACTOR; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MAF; SEX FACTORS;

EID: 84890249951     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12211     Document Type: Article

References (40)

1. Zámeníkova A. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer. Expert Rev Hematol 2010;1:45-56.
2. Camgoz A, Gencer EB, Ural AU, Baran Y. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leuk Lymphoma 2013;54:1279-87.
3. Razga F, Jurcek T, Zackova D, Dvorakova D, Toskova M, Jeziskova I, Mayer J, Racil Z. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. Mol Diagn Ther 2012;16:251-9.
4. Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma 2011;52:2139-47.
5. Richardson DB, Terschüren C, Pohlabeln H, Jöckel KH, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control 2008;19:43-50.
6. Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med 2012;55:779-85.
7. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010;704:152-9.
8. Kosaka T, Yoshino J, Inui K, et al. Involvement of NAD(P)H:quinone oxidoreductase 1 and superoxide dismutase polymorphisms in ulcerative colitis. DNA Cell Biol 2009;28:625-31.
9. Lee IT, Luo SF, Lee CW, Wang SW, Lin CC, Chang CC, Chen YL, Chau LY, Yang CM. Overexpression of HO-1 protects against TNF-alpha-mediated airway inflammation by down-regulation of TNFR1-dependent oxidative stress. Am J Pathol 2009;175:519-32.
10. Gao SS, Chen XY, Zhu RZ, Choi BM, Kim BR. Sulforaphane induces glutathione S-transferase isozymes which detoxify aflatoxin B(1)-8, 9-epoxide in AML 12 cells. BioFactors 2010;36:289-96.
11. Malfatti MA, Wu RW, Felton JS. The effect of UDP-glucuronosyltransferase 1A1 expression on the mutagenicity and metabolism of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine in CHO cells. Mutat Res 2005;570:205-14.
12. Malhotra D, Portales-Casamar E, Singh A, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 2010;38:5718-34.
13. Jyrkkanen HK, Kuosmanen S, Heinanieni M, Laitinen H, Kansanen E, Mella-aho E, Leinonen H, Yla-Herttuala S, Levonen AL. Novel insights into the regulation of antioxidant-response-element mediated gene expression by electrophiles: induction of the transcriptional repressor BACH1 by Nrf2. Biochem J 2011;440:167-74.
14. Zhu M, Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun 2001;289:212-9.
15. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011;16:123-40.
16. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 2001;98:4611-6.
17. Li YJ, Takizawa H, Azuma A, Kohyama T, Yamauchi Y, Takahashi S, Yamamoto M, Kawada T, Kudoh S, Sugawara I. Disruption of Nrf2 enhances inflammatory responses induced by low-dose diesel exhaust particles in mice. Clin Immunol 2008;128:366-73.
18. Khort TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006;66:11580-4.
19. Ramos-Gomez M, Kwak K, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001;98:3410-5.
20. Guerrero-Beltran CE, Calderon-Oliver M, Tapia E, Medina-Campos ON, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Ortiz-Vega KM, Franco M, Pedraza-Chaverri J. Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicol Lett 2010;192:278-85.
21. Marzec JM, Christie JD, Reddy SP, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007;21:2237-46.
22. Cordova EJ, Velazquez-Cruz R, Centeno F, Baca V, Orozco L. The NRF2 gene variant, -653G/A, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus 2010;19:1237-42.
23. Von Otter M, Landgren S, Nilsson S, et al. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev 2010;131:105-10.
24. Von Otter M, Landgren S, Nilsson S, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 2010;2:11-36.
25. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 2005;25:8044-51.
26. Shavit JA, Motohashi H, Onodera K, Akasaka J, Yamamoto M, Engel JD. Impaired megakaryopoiesis and behavioral defects in mafG-null mutant mice. Genes Dev 1998;12:2164-74.
27. Motohashi H, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci USA 2004;101:6379-84.
28. Emison ES, Garcia-Barcelo M, Grice EA, et al. Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet 2010;87:60-74.
29. Marinescu VD, Kohane IS, Riva A. The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. Nucleic Acids Res 2005;33:D91-7.
30. Wang X, Chorley BN, Pittman GS, Kleeberger SR, Brothers J 2nd, Liu G, Spira A, Bell DA. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS One 2010;5:e11934.
31. Onodera K, Shavit JA, Motohashi H, Katsuoka F, Akasaka JE, Engel JD, Yamamoto M. Characterization of the murine mafF gene. J Biol Chem 1999;274:21162-9.
32. Onodera K, Shavit JA, Motohashi H, Yamamoto M, Engel JD. Perinatal synthetic lethality and hematopoietic defects in compound mafG:mafK mutant mice. EMBO J 2000;19: 1335-45.
33. Chikova A, Bernard HU, Shchepotin IB, Grando SA. New associations of thegenetic polymorphisms in nicotinic receptor genes with the risk of lung cancer. Life Sci 2012;91:1103-8.
34. Junjie X, Songyao J, Minmin S, Yanyan S, Baiyong S, Xiaxing D, Jiabin J, Xi Z, Hao C. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer 2012;12:57.
35. Friedrich K, Rupp C, Hov JR, et al. A frequent PNPLA3 variant is a sex specific disease modifier in PSC patients with bile duct stenosis. PLoS One 2013;8:e58734.
36. Higaki J, Baba S, Katsuy T, Sato N, Mannami T, Ogata J, Ogihara T. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation 2000;101:2060-5.
37. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer Ej, Myers RH, Levy D. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998;97:1766-72.
38. Stankovic A, Zivkovic M, Alavantic D. Angiotensin I-converting enzyme gene polymorphism in a Serbian population: a gender-specific association with hypertension. Scand J Clin Lab Invest 2002;62:469-75.
39. Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. Nat Rev Genet 2008;9:911-22.
40. Nanashima K, Mawatari T, Tahara N, et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb) 2012;92:253-9.